Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

ELUT 11.13.2024

Full Press ReleaseSEC FilingsOur ELUT Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - Elutia Announces Full Launch of EluPro™ Following Strong Initial Demand
  • 01.06.2025 - Elutia Announces EluPro™ GPO Agreement with Southern Strategic Sourcing Partners
  • 12.02.2024 - Elutia Awarded Cardiac Rhythm Management Devices Agreement with Premier, Inc.

Recent Filings

  • 12.11.2024 - 4 Statement of changes in beneficial ownership of securities
  • 11.14.2024 - EX-99.1 EX-99.1
  • 11.14.2024 - 8-K Current report

SILVER SPRING, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, Matt Ferguson, Chief Financial Officer, and Dr. Michelle LeRoux Williams, Chief Scientific Officer, will participate in 1x1 investor meetings at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21, 2024.

Institutional investors interested in meeting with management during the conference may reach out to their Canaccord representative.

About ElutiaElutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visitwww.Elutia.com.

Investors:Matt SteinbergFINN Partnersmatt.steinberg@finnpartners.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com